



Healthcare Leaders Income ETF

**Interim Financial Statements
(Unaudited)**

June 30, 2017

Healthcare Leaders Income ETF

STATEMENTS OF FINANCIAL POSITION		
(Unaudited)		
As at	June 30, 2017	December 31, 2016
Assets		
Current assets		
Investments	\$ 217,462,752	\$ 111,286,782
Receivable for options purchased	74,712	-
Cash	8,355,679	2,082,686
Dividends receivable	341,207	266,937
Subscription receivable	1,426,470	-
Unrealized appreciation on foreign currency forward contracts (Note 6)	5,642,826	-
	\$ 233,303,646	\$ 113,636,405
Liabilities		
Current liabilities		
Payable for investments purchased	1,408,910	-
Distributions payable (Note 4)	1,536,623	811,772
Payable for option contracts written	757,431	344,220
Unrealized depreciation on foreign currency forward contracts (Note 6)	-	2,279,778
	\$ 3,702,964	\$ 3,435,770
Net assets attributable to holders of redeemable units	\$ 229,600,682	\$ 110,200,635
Net assets attributable to holders of redeemable units		
Series A	\$ 215,111,911	\$ 110,200,635
Series U (CAD)	14,488,771	N/A
Series U (USD)	11,145,208	N/A
Number of redeemable units outstanding (Note 4)		
Series A	24,824,053	13,924,053
Series U	1,300,000	N/A
Net assets attributable to holders of redeemable units per unit		
Series A	\$ 8.67	\$ 7.91
Series U (CAD)	11.15	N/A
Series U (USD)	8.57	N/A

The accompanying notes are an integral part of these financial statements.

Healthcare Leaders Income ETF

STATEMENTS OF COMPREHENSIVE INCOME (LOSS)			
(Unaudited)			
For the period ended June 30,	2017		2016
Income			
Net gain (loss) on investments			
Dividends	\$	2,056,895	\$ 1,658,270
Net realized gain (loss) on sale of investments		1,474,500	3,226,213
Net change in unrealized appreciation (depreciation) of investments		15,780,531	(8,395,251)
Net gain (loss) on investments		19,311,926	(3,510,768)
Net gain (loss) on derivatives			
Net realized gain (loss) on options		(413,682)	411,275
Net realized gain (loss) on foreign exchange		(2,973,131)	4,493,682
Net change in unrealized appreciation (depreciation) on options		115,352	(71,928)
Net change in unrealized appreciation (depreciation) of foreign exchange		7,833,551	2,884,088
Net gain (loss) on derivatives		4,562,090	7,717,117
Total income (net)	\$	23,874,016	\$ 4,206,349
Expenses (Note 5)			
Management fees	\$	829,296	\$ 614,999
Withholding taxes		230,519	193,001
Unitholder reporting costs		164,919	147,956
Audit fees		5,091	6,254
Transfer agency fees		6,259	8,339
Custodian fees and bank charges		40,987	33,007
Independent Review Committee fees		11,996	11,058
Filing fees		25,985	34,805
Legal fees		7,577	23,336
Transaction costs (Note 8)		136,898	63,851
Total expenses	\$	1,459,527	\$ 1,136,606
Increase (decrease) in net assets attributable to holders of redeemable units	\$	22,414,489	\$ 3,069,743
Increase (decrease) in net assets attributable to holders of redeemable units - Series A	\$	22,015,972	\$ 3,069,743
Increase (decrease) in net assets attributable to holders of redeemable units - Series U		398,517	N/A
Increase (decrease) in net assets attributable to holders of redeemable units per unit - Series A (Note 4)	\$	1.09	\$ 0.20
Increase (decrease) in net assets attributable to holders of redeemable units per unit - Series U (Note 4)		0.62	N/A

The accompanying notes are an integral part of these financial statements.

Healthcare Leaders Income ETF

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS ALL SERIES (Unaudited)			
For the period ended June 30,		2017	2016
Net assets attributable to holders of redeemable units beginning of period	\$	110,200,635	\$ 137,229,196
Increase (decrease) in net assets attributable to holders of redeemable units		22,414,489	3,069,743
Redeemable unit transactions			
Proceeds from issue of redeemable units		104,640,378	-
Reinvestment of distributions to holders of redeemable units		-	257
Redemption of redeemable units		-	(19,080,437)
Cancellation of redeemable units		-	(1,047,018)
Net unitholders' transactions	\$	104,640,378	\$ (20,127,198)
Distributions to holders of redeemable units			
Net investment income		(7,654,820)	(5,184,174)
Total distributions to holders of redeemable units	\$	(7,654,820)	\$ (5,184,174)
Net assets attributable to holders of redeemable units end of period	\$	229,600,682	\$ 114,987,567

The accompanying notes are an integral part of these financial statements.

Healthcare Leaders Income ETF

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS SERIES A (Unaudited)

For the period ended June 30,	2017	2016
Net assets attributable to holders of redeemable units beginning of period	\$ 110,200,635	\$ 137,229,196
Increase (decrease) in net assets attributable to holders of redeemable units	22,015,972	3,069,743
Redeemable unit transactions		
Proceeds from issue of redeemable units	90,267,008	-
Reinvestment of distributions to holders of redeemable units	-	257
Redemption of redeemable units	-	(19,080,437)
Cancellation of redeemable units	-	(1,047,018)
Net unitholders' transactions	\$ 90,267,008	\$ (20,127,198)
Distributions to holders of redeemable units		
Net investment income	(7,371,704)	(5,184,174)
Total distributions to holders of redeemable units	\$ (7,371,704)	\$ (5,184,174)
Net assets attributable to holders of redeemable units end of period	\$ 215,111,911	\$ 114,987,567

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS SERIES U (Unaudited)

For the period from February 9, 2017 (commencement of operations) to June 30, 2017

	2017
Net assets attributable to holders of redeemable units beginning of period	\$ -
Increase (decrease) in net assets attributable to holders of redeemable units	398,517
Redeemable unit transactions	
Proceeds from issue of redeemable units	14,373,370
Net unitholders' transactions	\$ 14,373,370
Distributions to holders of redeemable units	
Net investment income	(283,116)
Total distributions to holders of redeemable units	\$ (283,116)
Net assets attributable to holders of redeemable units end of period	\$ 14,488,771

The accompanying notes are an integral part of these financial statements.

Healthcare Leaders Income ETF

STATEMENTS OF CASH FLOWS		
(Unaudited)		
For the period ended June 30,	2017	2016
Operating activities		
Increase (decrease) in net assets attributable to holders of redeemable units	\$ 22,414,489	\$ 3,069,743
Add (deduct) items not affecting cash		
Realized (gain) loss on sale of investments	(1,474,500)	(3,226,213)
Realized (gain) loss on options	413,682	(411,275)
Change in unrealized (appreciation) depreciation of investments	(15,780,531)	8,395,251
Change in unrealized (appreciation) depreciation on options	(115,352)	71,928
Change in unrealized (appreciation) depreciation of foreign exchange	(7,833,551)	(2,884,088)
Proceeds from sale of investments	57,529,090	21,432,941
Purchases of investments	(52,709,625)	(17,788,006)
Net change in non-cash assets and liabilities	(163,323)	49,305
Net cash flow provided by (used in) operating activities	\$ 2,280,379	\$ 8,709,586
Financing activities**		
Proceeds from redeemable units issued	10,922,583	-
Cancellation of redeemable units	-	(1,047,018)
Redemption of redeemable units	-	(931,224)
Distributions paid to holders of redeemable units (net of reinvestments)	(6,929,969)	(5,319,499)
Net cash flow provided by (used in) financing activities	\$ 3,992,614	\$ (7,297,741)
Net increase (decrease) in cash during the period	6,272,993	1,411,845
Cash, beginning of the period	2,082,686	595,470
Cash, end of the period	\$ 8,355,679	\$ 2,007,315
Supplemental disclosure of cash flow information		
Dividends received, net of withholding taxes*	\$ 1,752,106	\$ 1,523,865

*included in operating activities

**net cash inflows (outflows) excludes trades that were not settled in cash (in-kind trades).

The accompanying notes are an integral part of these financial statements.



Healthcare Leaders Income ETF

SCHEDULE OF INVESTMENTS (Unaudited)				
As at June 30, 2017				
Number of Shares	Security	Average Cost (\$)	Carrying Value (\$)	% of Net Assets
EQUITIES				
123,780	AbbVie Inc.	10,144,892	11,656,206	5.1
34,490	Allergan PLC	11,039,184	10,888,527	4.7
48,194	Amgen Inc.	10,095,090	10,779,798	4.7
44,091	Anthem, Inc.	9,450,769	10,772,509	4.7
236,444	AstraZeneca PLC ADR	8,993,639	10,468,010	4.6
303,209	Boston Scientific Corporation	8,943,948	10,915,513	4.7
148,900	Bristol-Myers Squibb Company	11,001,717	10,774,935	4.7
66,111	Celgene Corporation	10,119,715	11,150,425	4.9
98,621	Eli Lilly and Company	9,675,096	10,540,909	4.6
118,529	Gilead Sciences, Inc.	12,387,781	10,895,421	4.7
188,433	GlaxoSmithKline PLC ADR	10,198,148	10,552,238	4.6
65,522	Johnson & Johnson	9,318,437	11,257,009	4.9
98,978	Medtronic Public Limited Company	9,713,408	11,408,167	5.0
126,932	Merck & Co., Inc.	9,784,144	10,565,018	4.6
99,815	Novartis AG ADR	10,492,913	10,820,194	4.7
243,770	Pfizer Inc.	10,134,546	10,634,060	4.6
77,018	Quest Diagnostics Incorporated	8,126,659	11,118,587	4.8
59,603	Stryker Corporation	9,860,788	10,742,462	4.7
44,797	UnitedHealth Group Incorporated	9,367,756	10,787,340	4.7
132,515	Zoetis Inc. Class A	9,435,328	10,735,424	4.7
Total equities		198,283,958	217,462,752	94.7

Healthcare Leaders Income ETF

SCHEDULE OF INVESTMENTS (continued) (Unaudited)

As at June 30, 2017

Number of Shares	Security	Average Cost (\$)	Carrying Value (\$)	% of Net Assets
OPTIONS				
Healthcare Issuers				
42,300	AstraZeneca PLC - Aug 2017 @ USD \$32.5	58,849	74,712	-
(17,600)	AbbVie Inc. - Jul 2017 @ USD \$72	(15,338)	(27,200)	-
(11,900)	AbbVie Inc. - Jul 2017 @ USD \$73	(18,888)	(10,200)	-
(4,900)	Allergan PLC - Jul 2017 @ USD \$240	(26,849)	(38,818)	-
(3,300)	Allergan PLC - Jul 2017 @ USD \$250	(21,388)	(5,272)	-
(6,800)	Amgen Inc. - Jul 2017 @ USD \$165	(27,614)	(73,564)	(0.1)
(4,600)	Amgen Inc. - Jul 2017 @ USD \$175	(22,512)	(10,753)	-
(5,800)	Anthem, Inc. - Jul 2017 @ USD \$192.5	(24,123)	(10,470)	-
(3,900)	Anthem, Inc. - Jul 2017 @ USD \$195	(17,281)	(4,027)	-
(32,300)	AstraZeneca PLC ADR - Jul 2017 @ USD \$35	(46,912)	(46,143)	-
(21,800)	AstraZeneca PLC ADR - Jul 2017 @ USD \$35.5	(40,369)	(26,896)	-
(49,700)	Boston Scientific Corporation - Jul 2017 @ USD \$28	(34,223)	(25,173)	-
(43,100)	Boston Scientific Corporation - Jul 2017 @ USD \$28.5	(31,299)	(11,475)	-
(21,200)	Bristol-Myers Squibb Company - Jul 2017 @ USD \$56	(25,192)	(33,865)	-
(14,300)	Bristol-Myers Squibb Company - Jul 2017 @ USD \$58	(24,837)	(11,700)	-
(9,400)	Celgene Corporation - Jul 2017 @ USD \$126	(28,795)	(67,387)	(0.1)
(6,300)	Celgene Corporation - Jul 2017 @ USD \$134	(31,665)	(10,391)	-
(13,700)	Eli Lilly and Company - Jul 2017 @ USD \$83	(22,792)	(16,725)	-
(9,300)	Eli Lilly and Company - Jul 2017 @ USD \$85.5	(14,023)	(3,261)	-
(15,500)	Gilead Sciences, Inc. - Jul 2017 @ USD \$65	(24,166)	(119,773)	(0.1)
(10,500)	Gilead Sciences, Inc. - Jul 2017 @ USD \$70.5	(27,360)	(20,727)	-
(26,800)	GlaxoSmithKline PLC - Jul 2017 @ USD \$44	(18,464)	(5,221)	-
(18,100)	GlaxoSmithKline PLC - Jul 2017 @ USD \$44.5	(13,167)	(2,351)	-
(9,300)	Johnson & Johnson - Jul 2017 @ USD \$134	(22,839)	(15,700)	-
(10,700)	Johnson & Johnson - Jul 2017 @ USD \$137	(28,023)	(5,280)	-
(14,100)	Medtronic Public Limited Company - Jul 2017 @ USD \$89	(19,920)	(16,847)	-
(9,500)	Medtronic Public Limited Company - Jul 2017 @ USD \$90	(10,786)	(6,169)	-
(18,000)	Merck & Co., Inc. - Jul 2017 @ USD \$64.5	(16,399)	(19,870)	-
(12,200)	Merck & Co., Inc. - Jul 2017 @ USD \$66.5	(16,316)	(4,278)	-
(31,400)	Novartis AG - Jul 2017 @ USD \$85	(58,504)	(26,506)	-
(50,400)	Pfizer Inc. - Jul 2017 @ USD \$34.5	(25,333)	(5,891)	-
(11,400)	Stryker Corporation - Jul 2017 @ USD \$140	(37,195)	(20,727)	-
(4,600)	UnitedHealth Group Incorporated - Jul 2017 @ USD \$182.5	(22,776)	(31,513)	-
(4,100)	UnitedHealth Group Incorporated - Jul 2017 @ USD \$190	(17,134)	(8,892)	-
(16,800)	Zoetis Inc. - Jul 2017 @ USD \$63.5	(17,746)	(8,727)	-
(19,300)	Zoetis Inc. - Jul 2017 @ USD \$64	(22,975)	(5,640)	-
	Total options	(814,354)	(682,720)	(0.3)
	Total investments	197,469,604	216,780,032	94.4
	Foreign currency forward contracts (Note 6)		5,642,826	2.5
	Other assets less liabilities		7,177,824	3.1
	Net assets attributable to holders of redeemable units		229,600,682	100.0

Healthcare Leaders Income ETF

NOTES TO THE INTERIM FINANCIAL STATEMENTS (Unaudited)

June 30, 2017

1. GENERAL INFORMATION

Healthcare Leaders Income ETF (the “Fund”) is an investment fund established under the laws of the Province of Ontario pursuant to a Declaration of Trust dated November 19, 2014 and as amended and restated, being the inception date. There was no significant activity in the Fund from the date of inception to commencement of operations on December 18, 2014. On December 18, 2014, the Fund completed an initial public offering of 9,500,000 units at \$10.00 per unit for gross proceeds of \$95,000,000. On January 13, 2015, an overallotment option was exercised for an additional 259,149 units at a price of \$10.00 per unit for gross proceeds of \$2,591,490. On March 13, 2015, the Fund completed a secondary offering of 3,000,000 units at \$10.10 per unit for gross proceeds of \$30,300,000. Related to this offering an overallotment option was exercised for an additional 450,000 units at a price of \$10.10 per unit for gross proceeds of \$4,545,000. On May 7, 2015, the Fund completed a secondary offering of 2,360,000 units at \$10.20 per unit for gross proceeds of \$24,072,000. Related to this offering an overallotment option was exercised for an additional 145,000 units at a price of \$10.20 per unit for gross proceeds of \$1,479,000. The address of the Fund’s registered office is 710 Dorval Drive, Oakville, Ontario, L6K 3V7.

The Fund’s investment objectives are to provide unitholders with the opportunity for capital appreciation, monthly cash distributions and lower overall volatility of Portfolio returns than would otherwise be experienced by owning Equity Securities of the Healthcare Leaders directly. As part of the investment strategy, the Fund will invest in an equally-weighted portfolio of Equity Securities of 20 Healthcare Issuers from the Healthcare Leaders Investable Universe that have a market capitalization of at least US\$5 billion at the time of investment and have options in respect of their Equity Securities listed on a recognized options exchange.

On September 19, 2016, unitholders approved the conversion of the units of the Fund into an Exchange Traded Fund (“ETF”) effective October 24, 2016 and the name of the Fund changed to Healthcare Leaders Income ETF. The units began trading as an ETF under the symbol HHL. Prior to the conversion, units traded under the symbol HHL.UN as a closed end fund. On February 9, 2017, the Fund launched a USD series U unit of the Fund. The series U unit began trading under the symbol HHL.U.

2. BASIS OF PRESENTATION

These interim financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) applicable to the preparation of interim financial statements, including International Accounting Standard 34, Interim Financial Reporting and should be read in conjunction with the annual financial statements for the period ended December 31, 2016 which have been prepared in accordance with IFRS. These interim financial statements were authorized for issue by Harvest Portfolios Group Inc. (the “Manager”) on August 24, 2017.

3. SIGNIFICANT ACCOUNTING POLICIES

Financial instruments

The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments not measured at fair value through profit or loss (FVTPL). Transaction costs on financial assets and liabilities at FVTPL are expensed as incurred. Regular way purchases and sales of financial assets are recognized at their trade date. The Fund’s investments and derivative assets and liabilities are measured at fair value through profit or loss (FVTPL), including investments which have been designated at FVTPL. Derivative assets and liabilities are classified as held-for-trading (HFT). The Fund’s obligation for net assets attributable to holders of redeemable units is presented at the redemption amount. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid, discounted, when appropriate, at the contract’s effective interest rate. Carrying values of other financial assets and liabilities at amortized cost approximate their fair values due to the short term to maturity. The Fund’s accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its net asset value (NAV) for transactions with unitholders. As at June 30, 2017 and December 31, 2016, there were no differences between the Fund’s NAV per security and its net assets per security calculated in accordance with IFRS.

Fair value of investments and derivatives

Investments and derivatives that are traded in an active market are valued at their closing prices through recognized public stock exchanges or through recognized investment dealers on the valuation date. The Fund uses the last traded market price that falls

Healthcare Leaders Income ETF

within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on specific facts and circumstances. Investments held are represented by equities. Derivatives held include options and foreign currency forward contracts.

Investments and derivatives held that are not traded in an active market are valued using valuation techniques, on such basis and in such a manner established by the Manager. The value of any security for which, in the opinion of the Manager, the published market quotations are not readily available shall be the fair value as determined by the Manager. The fair values of certain securities may be determined using valuation models that are based, in part, on assumptions that are not supported by observable market inputs. These methods and procedures may include, but are not limited to, performing comparisons with prices of comparable or similar securities, obtaining valuation related information from issuers and/or other analytical data relating to the investment and using other available indication of value. These values are independently assessed internally to ensure that they are reasonable. However, because of the inherent uncertainty of valuation, the estimated fair values for the aforementioned securities and interests may be materially different from the values that would be used had a ready market for the security existed. The fair values of such securities are affected by the perceived credit risks of the issuer, predictability of cash flows and length of time to maturity.

Classification of redeemable units

Under IFRS, IAS 32 Financial Instruments – Presentation requires that units or shares of an entity which include a contractual obligation for the issuer to repurchase or redeem them for cash or another financial asset be classified as a financial liability unless certain criteria are met. The Fund's units include different redemption rights and in some instances are at 95% of market value of the units on the exchange. As a result, the Fund's units contain multiple contractual obligations and are presented as financial liabilities as they do not meet the criteria for classification as equity.

Cash

Cash is comprised of cash on deposit.

Investment transactions and income recognition

Net realized gain (loss) on investments and net change in unrealized appreciation (depreciation) on investments are determined on an average cost basis. Dividend income is accounted for on the ex-dividend date.

Allocation of income and expense, and realized and unrealized capital gains and losses

Management fees directly attributable to a series are charged to that series. The Fund's shared operating expenses, income, and realized and unrealized capital gains and losses are generally allocated proportionately to each series based upon the relative net assets attributable to holders of redeemable units of each series. Realized and unrealized gains and losses from foreign currency forward contracts are allocated to Series A only.

Foreign currency translation

The Fund's subscriptions and redemptions are denominated in Canadian dollars which is also the Fund's functional and presentation currency. Purchases and sales of investments denominated in foreign currencies and foreign currency dividend and interest income are translated into Canadian dollars at the rate of exchange prevailing at the time of the transactions. Realized and unrealized foreign currency gains or (losses) on investments are included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on sale of investments" and "Net change in unrealized appreciation (depreciation) of investments", respectively. Realized and unrealized foreign currency gains or losses on assets, liabilities, and income, other than investments denominated in foreign currencies, are included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on foreign exchange" and "Net change in unrealized appreciation (depreciation) of foreign exchange", respectively. Foreign currency assets and liabilities in the Statements of Financial Position are translated into Canadian dollars on the statement date.

Foreign currency forward contracts

The Fund will enter into foreign currency forward contracts to hedge against exposure to foreign currency fluctuations. The fair value of these contracts is based on the difference between the contract rate and current forward market rate for the underlying currency at the measurement date applied to the contract's notional amount and adjusted for counterparty risk. Upon closing of a contract, the gain or loss is recorded as a net realized gain or loss on foreign exchange.

Offsetting financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the Statements of Financial Position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

Healthcare Leaders Income ETF

Redeemable units valuation

The NAV of each series on a particular date will be equal to each series' proportionate share of the assets of the Fund less each series' proportionate share of the liabilities of the Fund except for forwards which are only attributed to Series A, expressed in Canadian dollars at the applicable exchange rate on such date. The NAV and NAV per unit will be calculated on each Business Day. "Business Day" means any day on which the TSX is open for trading.

Options

An option is a contractual arrangement under which the seller (writer) grants the purchaser (holder) the right, but not the obligation, either to buy (a call option) or sell (a put option) at or by a set date or during a set period, a specific amount of securities or a financial instrument at a pre-determined price. The seller receives a premium from the purchaser in consideration for the assumption of a future securities price.

The premium paid for purchase options is included in the "Investments" on the Statement of Financial Position. The unrealized gain or loss is reflected in the Statement of Comprehensive Income (Loss) in "Net change in unrealized appreciation (depreciation) of options".

The premium received upon writing an option is recorded at cost as "Payable for option contracts written" in the Statements of Financial Position. As long as the position of the written option is maintained, the liability for written options is revalued at an amount equal to the current market value of the option. Any gain or loss resulting from revaluation is reflected in the Statements of Comprehensive Income (Loss) in "Net changes in unrealized appreciation (depreciation) of options".

The gain or loss on sale or expiry of options is reflected in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on sale of options".

Increase (decrease) in net assets attributable to holders of redeemable units per unit

"Increase (decrease) in net assets attributable to holders of redeemable units per unit" in the Statements of Comprehensive Income (Loss) represents the increase (decrease) in net assets attributable to holders of redeemable units per series, divided by the weighted average units outstanding for the financial period for the respective series.

Income and other taxes

The Fund qualifies as a mutual fund trust under the Income Tax Act (Canada). For tax purposes, the Fund has a December 31 year end. All of the Fund's net income for tax purposes and sufficient net capital gains realized in any period are required to be distributed to unitholders such that no income tax is payable by the Fund. As a result, the Fund does not record income taxes. Since the Fund does not record income taxes, the tax benefit of capital and non-capital losses has not been reflected in the statements of financial position as a deferred income tax asset. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Non-capital losses may be carried forward 20 years and applied against future taxable income. As at the Fund's last taxation year end, the Fund had \$1,030,884 of non-capital losses and \$3,610,035 net capital losses available to be carried forward for income tax purposes.

The Fund may incur withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown as a separate expense.

As the Manager is a resident of Ontario, the expenses paid by the Fund generally include HST of 13%. HST is calculated using the residency of unitholders in the Fund as at specific times, rather than the physical location of the Manager. A blended rate refund is filed with the Canada Revenue Agency on behalf of the Fund, in arrears, using each province's HST rate or GST rate in the case of non-participating provinces.

Critical accounting estimates and judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

- a) Fair value measurement of derivatives and securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. Refer to Note 7 for further information about the fair value measurement of the Fund's financial instruments.

Healthcare Leaders Income ETF

b) Classification and measurement of investment and application of the fair value option

In classifying and measuring financial instruments held by the Fund, the Manager is required to make significant judgments about whether or not the business of the Fund is to invest on a total return basis for the purpose of applying the fair value option for financial assets under IAS 39, Financial Instruments – Recognition and Measurement (IAS 39). The most significant judgments made include the determination that certain investments are held-for trading and that the fair value option can be applied to those which are not.

Accounting standards issued but not yet adopted

IFRS 9, Financial Instruments

The final version of IFRS 9, Financial Instruments, was issued by the IASB in July 2014 and will replace IAS 39 Financial Instruments – Recognition and Measurement. IFRS 9 introduces a model for classification and measurement, a single, forward-looking ‘expected loss’ impairment model and a substantially reformed approach to hedge accounting. The new single, principle based approach for determining the classification of financial assets is driven by cash flow characteristics and the business model in which an asset is held. The new model also results in a single impairment model being applied to all financial instruments, which will require more timely recognition of expected credit losses. It also includes changes in respect of own credit risk in measuring liabilities elected to be measured at fair value, so that gains caused by the deterioration of an entity’s own credit risk on such liabilities are no longer recognized in profit or loss. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, however, is available for early adoption. In addition, the own credit changes can be early applied in isolation without otherwise changing the accounting for financial instruments. The Manager continues to assess the impact of IFRS 9 by analyzing the Fund’s business model. The Manager does not expect any change in the measurement of the financial assets and liabilities of the Fund.

4. REDEEMABLE UNITS

The authorized capital of the Fund consists of an unlimited number of transferable units of each series, each of which represents an equal, undivided interest in the net assets of the Fund. Except as provided in the Declaration of Trust, all units have equal rights and privileges. Each unit is entitled to one vote at all meetings of unitholders and is entitled to participate equally in any and all distributions made by the Fund. The units trade on the TSX under the symbol HHL. As at June 30, 2017, the closing price for Series A and Series U units was \$8.66 and \$8.62 USD per unit respectively (December 31, 2016 – Series A \$7.92 per unit).

Upon conversion to an ETF, the Fund cancelled its normal course issuer bid program which allowed the Fund to purchase up to 1,526,051 units of the Fund for cancellation by way of a normal course issuer bid through the facilities of the Toronto Stock Exchange and other Canadian markets. During the period ended June 30, 2016, 130,400 units were purchased for cancellation for \$1,047,018.

Subscriptions and Redemptions

On any trading day, a designated broker or underwriter may place a subscription or redemption order for an integral multiple of the prescribed number of units of the ETF. A trading day is each day on which the TSX is opened for business.

If the subscription or redemption order is accepted, the ETF will issue or redeem units to/from the designated broker or underwriter by no later than the third trading day after the date on which the subscription or redemption order is accepted. For each prescribed number of units issued or redeemed, a designated broker or underwriter must deliver or receive payment consisting of:

- (a) A basket of applicable securities and cash in an amount sufficient so that the value of the securities, and the cash received is equal to the NAV of the units issued or redeemed; or
- (b) Cash in the amount equal to the NAV of the units issued or redeemed.

On any trading day, unitholders may redeem units for cash or exchange units for baskets of securities and cash. Units redeemed for cash may be redeemed at a redemption price per unit equal to 95% of the closing price for the units on the TSX on the effective day of the redemption, subject to a maximum redemption price per unit equal to NAV. Units exchanged for baskets of securities will be exchanged at a price equal to the NAV of the units on the effective date of the exchange request, payable by delivery of baskets of securities and cash. The units will be redeemed in the exchange.

Healthcare Leaders Income ETF

Prior to conversion to an ETF, unitholders had the option to surrender, prior to 5:00 p.m. (Toronto time) on the 10th business day before the last business day of the applicable month, for monthly redemption. Upon receipt by the Fund of the redemption notice, the unitholder was entitled to receive a price per unit equal to the lesser of:

- (a) 95% of the “market price” of the units on the principal market on which the units are quoted for trading during the 20 trading day period ending immediately before the monthly redemption date; and
- (b) 100% of the “closing market price” on the principal market on which the units are quoted for trading on the monthly redemption date.

Notwithstanding the monthly redemption price formula above, at no time did the Fund pay out redemption proceeds greater than the NAV per Unit as determined on the monthly redemption date for each Unit being redeemed. During the period ended June 30, 2016 115,380 units were redeemed and cancelled for \$931,224.

Prior to conversion and in accordance with the Fund prospectus, in addition to the monthly redemption rights, on an annual basis, commencing in June 2016, units could be surrendered for redemption at the Fund’s NAV per unit, subject to the required redemption notice period, for the second last business day of June and the unitholder will receive payment on or before the 15th business day of the following month. In 2016, 2,079,853 were redeemed and cancelled \$18,149,213.

The following units were issued, redeemed and/or cancelled during the period:

	Series A	Series U
Total outstanding as at January 1, 2016	15,372,990	-
Reinvestment of distributions to holders of redeemable units	30	-
Redeemable units redeemed	(2,195,233)	-
Cancellation of redeemable units	(130,400)	-
Total outstanding as at June 30, 2016	13,047,387	-
Total outstanding as at January 1, 2017	13,924,053	-
Redeemable units issued	10,900,000	1,300,000
Total outstanding as at June 30, 2017	24,824,053	1,300,000

The weighted average number of units outstanding during the period ended June 30, 2017 was 20,212,175 units (2016 – 15,160,830 units) for Series A and 646,207 (2016 – Nil) for Series U.

Distributions

The Fund intends to make monthly cash distributions to unitholders of record on the last business day of each month and pay such cash distributions on or before the 15th day of the following month. Beginning in January 2016, the Fund will annually determine and announce the distribution amount for the following year based upon the prevailing market conditions. The total distribution amount was \$7,654,820 (Series A \$7,371,704 and Series U \$283,116) for the period ended June 30, 2017 (2016 – \$5,184,174).

Prior to conversion to an ETF, the Fund made available to unitholders the opportunity to reinvest monthly distributions from the Fund in additional units by participating in a distribution reinvestment plan which would provide that cash distributions made by the Fund, at the election of a unitholder, be automatically reinvested in additional units, as applicable, on such unitholder’s behalf in accordance with the terms of the plan. Reinvestment of distributions occurred either through market purchases or units issued from treasury depending on whether the trading price of the units is above or below NAV and if units are available for purchase on the market. During the period ended June 30, 2016, a total of 30 reinvested units were issued from treasury and all other units were from market purchases. Upon conversion, the distribution reinvestment plan was discontinued. On July 5, 2017, a new distribution reinvestment plan was established by the Fund.

5. RELATED PARTY TRANSACTIONS AND OTHER EXPENSES

Management and service fees

Harvest Portfolios Group Inc. is the Manager of the Fund and is responsible for managing or arranging for managing the Fund’s overall business and operations and provides key management personnel to the Fund. The Manager retained Highstreet Asset Management Inc. (“Highstreet” or the “Investment Manager”) to provide investment management services to the Fund up until

Healthcare Leaders Income ETF

termination on March 31, 2016. Highstreet was paid a fee for its portfolio advisory service, from the management fee received from the Fund, calculated on the basis of the Fund's net assets. The Manager is entitled to a fee of 0.85% of the average daily NAV, plus applicable taxes, per annum of the Fund and paid monthly in arrears. Prior to conversion, the calculation was based on the average weekly NAV. At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund.

Operating expenses

The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of units, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee ("IRC"), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

Other expenses

The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to unitholders and other unitholder communications; a reasonable allocation of salaries, benefits and consulting fees; independent directors of the Manager and other administrative expenses and costs incurred in connection with the Fund's continuous public offering and other obligations. These expenses are allocated by the Manager on a reasonable basis, across all of the Harvest Portfolios Group Inc. funds, and series of each applicable fund. These expenses were \$149,773 for the period ended June 30, 2017 (2016 - \$137,303) and are included in the unitholder reporting costs on the Statements of Comprehensive Income (Loss).

6. FOREIGN CURRENCY FORWARD CONTRACTS

The Fund enters into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies. Foreign currency forward contracts entered into by the Fund represent a firm commitment to buy or sell a currency at a specified value and point in time based upon an agreed or contracted quantity. The value of the foreign currency forward contract is the difference between the contract rate and the current forward rate at the measurement date applied to the contract's notional amount and adjusted for counterparty risk. The unrealized gains or losses on the forward contract are reported as part of the change in unrealized appreciation or depreciation of foreign exchange in the Statements of Comprehensive Income (Loss) and allocated to Series A only until it is closed out or partially settled.

At June 30, 2017 and December 31, 2016, the Fund had entered into the following foreign currency forward contracts:

As at June 30, 2017					
Counterparty	Settlement Date	Purchased currency	Sold currency	Unrealized gain (loss)	Contract Price
Canadian Imperial Bank of Commerce - credit rating A+	August 23, 2017	CAD \$9,260,230	USD \$7,000,000	\$176,875	0.7559
Canadian Imperial Bank of Commerce - credit rating A+	August 23, 2017	CAD \$72,908,903	USD \$55,300,000	\$1,150,401	0.7585
Canadian Imperial Bank of Commerce - credit rating A+	August 23, 2017	CAD \$5,838,750	USD \$4,500,000	(\$550)	0.7707
National Bank - credit rating A	July 20, 2017	CAD \$62,340,750	USD \$46,350,000	\$2,164,307	0.7435
Royal Bank of Canada - credit rating AA-	July 20, 2017	CAD \$62,328,236	USD \$46,350,000	\$2,151,793	0.7436
Total		CAD \$212,676,869	USD \$159,500,000	\$5,642,826	

Healthcare Leaders Income ETF

As at December 31, 2016					
Counterparty	Settlement Date	Purchased currency	Sold currency	Unrealized gain (loss)	Contract Price
National Bank - credit rating A	January 20, 2017	CAD \$51,796,350	USD \$39,500,000	(\$1,163,570)	0.7626
Royal Bank of Canada - credit rating AA-	January 20, 2017	CAD \$51,790,623	USD \$39,500,000	(\$1,169,298)	0.7627
Royal Bank of Canada - credit rating AA-	January 20, 2017	CAD \$5,416,120	USD \$4,000,000	\$53,090	0.7385
Total		CAD \$109,003,093	USD \$83,000,000	(\$2,279,778)	

Offsetting of foreign currency forward contracts

In 2017, the Fund had foreign exchange settlements for its foreign currency forward contracts that meet the criteria for offsetting in the Statements of Financial Position. The following table presents the recognized financial instruments that were offset, as at June 30, 2017 and December 31, 2016.

June 30, 2017			
Financial assets and liabilities	Gross assets (liabilities)	Amounts eligible for offset	Net offset amounts
Derivative assets	\$5,643,376	(\$550)	\$5,642,826
Derivative liabilities	(\$550)	\$550	-

December 31, 2016			
Financial assets and liabilities	Gross assets (liabilities)	Amounts eligible for offset	Net offset amounts
Derivative assets	\$53,090	(\$53,090)	-
Derivative liabilities	(\$2,332,868)	\$53,090	(\$2,279,778)

7. FINANCIAL RISK MANAGEMENT

Investment activities of the Fund expose it to a variety of financial risks: credit risk, liquidity risk and market risk (including interest rate risk, other price risk and currency risk). The Manager seeks to minimize these risks by employing experienced portfolio managers that will manage the security portfolios of the Fund on a daily basis according to market events and the investment objectives of the Fund. To assist in managing risk, the Manager also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy and securities regulations.

Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The value of securities in the Fund's portfolio may be affected by the stock market conditions rather than each company's performance. Developments in the market are affected by general economic and financial conditions. Political, social and environmental factors can also affect the value of any investment.

As at June 30, 2017, 94.7% (December 31, 2016 – 101.0%) of the Fund's net assets attributable to holders of redeemable units were traded on public stock exchanges. If equity prices on these exchanges had increased or decreased by 5%, as at period end, with all other factors remaining constant, net assets attributable to holders of redeemable units would have increased or decreased by approximately \$10,873,138 (December 31, 2016 - \$5,564,339).

In practice, the actual trading results may differ and the difference could be material.

Currency risk

Currency risk is the risk that the value of investments denominated in currencies other than the functional currency of the Fund will fluctuate as a result of changes in foreign exchange rates. When a Fund buys an investment priced in a foreign currency and the exchange rate between the Canadian dollar and the foreign currency changes unfavorably, it could reduce the value of the Fund's investment.

Healthcare Leaders Income ETF

The table below summarizes the Fund's net exposure to currency risk. Amounts shown are based on the carrying value of monetary and non-monetary assets (including derivatives and the underlying principal (notional) amount of forward currency contracts, if any).

As at June 30, 2017				
Currency	Currency exposure*	Forward contracts*	Net currency exposure*	As a % of net assets
U.S. Dollars	\$219,744,193	\$ 207,034,042	\$12,710,151	5.5

*In Canadian dollars

As at December 31, 2016				
Currency	Currency exposure*	Forward contracts*	Net currency exposure*	As a % of net assets
U.S. Dollars	\$111,441,541	\$111,282,870	\$158,671	0.1

*In Canadian dollars

The non-monetary currency exposure is \$216,780,033 (December 31, 2016 - \$110,942,562) and the monetary exposure is \$2,964,160 (December 31, 2016 - \$498,979).

As at June 30, 2017, if the Canadian dollar had strengthened or weakened by 5% in relation to U.S. dollar, with all other variables held constant, the Fund's net assets attributable to holders of redeemable units would have increased or decreased, respectively, by approximately \$635,508 or 0.3% (December 31, 2016 - \$7,934 or 0.01%). In practice, the actual results may differ from this sensitivity analysis and the difference could be material.

As all of the securities in the portfolio investments are denominated in U.S. dollars and expected dividends and premiums from call options received, if applicable, are in U.S. dollars, the Fund enters into a forward currency contract on substantially all of the value of the proportionate share of Series A portfolio investments back to the Canadian dollar at all times.

Interest rate risk

Interest rate risk arises from the possibility that changes in interest rates will affect future cash flows or fair value of financial instruments. Interest rate risk arises when the Fund invests in interest-bearing financial instruments. As at June 30, 2017 and December 31, 2016, the Fund did not hold any bonds or money market instruments; therefore, the Fund has no significant exposure to interest rate risk.

Liquidity risk

Liquidity risk is defined as the risk that a fund may not be able to settle or meet its obligations on time or at a reasonable price. The Fund is exposed to redemption of units as described in Note 4. Since the settlement of redemptions is primarily by delivery of securities, the Fund is not exposed to any significant liquidity risk. Therefore in order to maintain sufficient liquidity, the Fund primarily invests in securities that are actively traded in public markets and can be readily disposed of to raise liquidity. In addition, the Fund retains sufficient cash and cash equivalent positions to maintain liquidity.

As at June 30, 2017 and December 31, 2016, all of the Fund's financial liabilities had maturities of less than three months.

Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund.

All transactions executed by the Fund in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

The Fund enters into foreign currency forward contracts which are exposed to credit risk. The maximum credit risk exposure is the unrealized gain (loss) on the forward contracts.

As at June 30, 2017 and December 31, 2016, the Fund did not have significant credit risk exposure. All cash held by the fund is held with a reputable and regulated financial institution.

Healthcare Leaders Income ETF

Fair value of financial instruments

The Fund classifies fair value measurements within a hierarchy which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3: Inputs for the asset or liability that are not based on observable market data.

The table below summarizes the fair value of the Fund's financial instruments using the following fair value hierarchy:

Transfers between levels of the fair value hierarchy are deemed to have occurred at the beginning of the reporting period.

Securities classification:

Investments at fair value as at June 30, 2017				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Totals (\$)
Financial Assets				
Equities				
Common Stock	185,622,310	-	-	185,622,310
ADR	31,840,442	-	-	31,840,442
Derivatives				
Options	74,712	-	-	74,712
Foreign currency forward contract	-	5,642,826	-	5,642,826
Total Financial Assets	217,537,464	5,642,826	-	223,180,290
Financial Liabilities				
Derivatives				
Options	(757,432)	-	-	(757,432)
Total Financial Liabilities	(757,432)	-	-	(757,432)
Investments at fair value as at December 31, 2016				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Totals (\$)
Financial Assets				
Equities				
Common Stock	95,244,852	-	-	95,244,852
ADR	16,041,930	-	-	16,041,930
Total Financial Assets	111,286,782	-	-	111,286,782
Financial Liabilities				
Derivatives				
Options	(344,220)	-	-	(344,220)
Foreign currency forward contract	-	(2,279,778)	-	(2,279,778)
Total Financial Liabilities	(344,220)	(2,279,778)	-	(2,623,998)

There were no Level 3 securities held by the Fund as at June 30, 2017 and December 31, 2016, and there were no transfers between Level 1 and Level 2 for the period ended June 30, 2017 or for the year ended December 31, 2016.

Healthcare Leaders Income ETF

The value of the equities and options is based on quoted prices. The value of the foreign currency forward contract is determined as the difference between the contract rate and the current forward rate at the measurement date applied to the contract's notional amount and adjusted for counterparty risk.

Concentration Risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, product type, industry, sector or counterparty type. The following is a summary of the Fund's concentration risk by geography and segment.

Geography:

As at	June 30, 2017		December 31, 2016	
Country of Issue	\$*	% of net assets	\$*	% of net assets
United States of America	216,780,032	94.4	110,942,562	100.7
Totals	216,780,032	94.4	110,942,562	100.7

*Stated in Canadian dollars

Market Segment (percentage of net assets attributable to holders of redeemable units):

	June 30, 2017	December 31, 2016
	% of net assets	% of net assets
EQUITIES		
Healthcare Issuers	94.7	101.0
OPTIONS		
Healthcare Issuers	(0.3)	(0.3)
Total	94.4	100.7

8. SOFT DOLLAR COMMISSIONS

Brokerage commissions paid to certain brokers may, in addition to paying for the cost of brokerage services in respect of security transactions, also provide for the cost of investment research services provided to the investment manager. The value of such research services included in commissions paid to brokers for the periods ended June 30, 2017 and 2016 amounted to \$nil.

Healthcare Leaders Income ETF

Head Office

710 Dorval Drive, Suite 209
Oakville, ON L6K 3V7
Phone Number: 416.649.4541
Toll Free: 866.998.8298
Fax Number: 416.649.4542
Email: info@harvestportfolios.com

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in the Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.